Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.54 |
| ▸ | SRC | P12931 | 6/20 | 0.54 |
| ▸ | AURKA | O14965 | 1/20 | 0.54 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.54 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.54 |
| ▸ | TEK | Q02763 | 3/20 | 0.53 |
| ▸ | JAK2 | O60674 | 3/20 | 0.52 |
| ▸ | JAK3 | P52333 | 3/20 | 0.52 |
| ▸ | JAK1 | P23458 | 1/20 | 0.52 |
| ▸ | BTK | Q06187 | 2/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KIT | P10721 | 3/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12120466 | 0.91 | SRC (0.52) | KDRSRCAURKAAURKBJAK2 | |
| SCHEMBL12120698 | 0.87 | AURKA (0.67) | KDRSRCAURKAIKBKEAURKB | |
| SCHEMBL1320583 | 0.87 | KDR (0.56) | KDRSRCAURKAAURKBTEK | |
| SCHEMBL12120714 | 0.87 | KDR (0.52) | KDRSRCAURKAIKBKEAURKB | |
| SCHEMBL14295949 | 0.86 | KDR (0.53) | KDRSRCAURKAAURKBTEK | |
| SCHEMBL12120704 | 0.85 | SRC (0.75) | KDRSRCAURKAIKBKEAURKB | |
| SCHEMBL12120701 | 0.85 | SRC (0.64) | KDRSRCAURKAIKBKEAURKB | |
| SCHEMBL12120715 | 0.82 | SRC (0.65) | KDRSRCAURKAIKBKEAURKB | |
| SCHEMBL1317740 | 0.80 | ABL1 (0.53) | KDRSRCAURKAJAK2JAK3 | |
| SCHEMBL1318725 | 0.78 | BTK (0.60) | SRCJAK2JAK3JAK1BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8980899-B2 | Methods of inhibiting Ire1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-03-17 | — | — | US | disclosed |
| US-20120322814-A1 | METHODS OF INHIBITING IRE1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-12-20 | — | — | US | disclosed |
| US-20110275651-A1 | FUSED RING HETEROARYL KINASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322814-A1 | METHODS OF INHIBITING IRE1 | XBP1, DNAJC10, HSPA5 | KDR 4859/4885SRC 4225/4885AURKA 4253/4885 |
| US-20110275651-A1 | FUSED RING HETEROARYL KINASE INHIBITORS | CNKSR1, MAP3K20, TTK | KDR 837/4885SRC 180/4885AURKA 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.